Compare SIM & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIM | TFX |
|---|---|---|
| Founded | 1969 | 1943 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.6B |
| IPO Year | 2002 | 1994 |
| Metric | SIM | TFX |
|---|---|---|
| Price | $30.80 | $106.55 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $140.29 |
| AVG Volume (30 Days) | 1.0K | ★ 783.4K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.29% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,992,713,000.00 |
| Revenue This Year | N/A | $46.78 |
| Revenue Next Year | N/A | $3.86 |
| P/E Ratio | $32.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.60 | $100.18 |
| 52 Week High | $34.59 | $142.96 |
| Indicator | SIM | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 53.73 | 40.28 |
| Support Level | $26.61 | $102.03 |
| Resistance Level | $33.00 | $108.01 |
| Average True Range (ATR) | 0.61 | 2.92 |
| MACD | 0.11 | -1.04 |
| Stochastic Oscillator | 66.20 | 8.12 |
Grupo Simec SAB de CV is a diversified producer, processor and distributor of SBQ steel and structural steel products with production and commercial operations. The group's SBQ products are used across a range of engineered end-user applications, including axles, hubs, and crankshafts for automobiles and light trucks, machine tools, and off-highway equipment. Its structural steel products are used in the non-residential construction market and other construction applications. Its segments are Mexico, Brazil, and the United States. The maximum of its sales is from the Mexico segment.
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.